| Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials D Bikard, CW Euler, W Jiang, PM Nussenzweig, GW Goldberg, X Duportet, ... Nature biotechnology 32 (11), 1146-1150, 2014 | 917 | 2014 |
| A platform for rapid prototyping of synthetic gene networks in mammalian cells X Duportet, L Wroblewska, P Guye, Y Li, J Eyquem, J Rieders, T Rimchala, ... Nucleic acids research 42 (21), 13440-13451, 2014 | 151 | 2014 |
| The biological interpretation of metabolomic data can be misled by the extraction method used X Duportet, RBM Aggio, S Carneiro, SG Villas-Bôas Metabolomics 8, 410-421, 2012 | 124 | 2012 |
| Rapid, modular and reliable construction of complex mammalian gene circuits P Guye, Y Li, L Wroblewska, X Duportet, R Weiss Nucleic acids research 41 (16), e156-e156, 2013 | 105 | 2013 |
| Improving sequence-specific antimicrobials by blocking dna repair D Bikard, CUI Lun, X Duportet, JF Rodriguez | 94 | 2017 |
| Development of sequence-specific antimicrobials based on programmable CRISPR-Cas nucleases D Bikard, C Euler, W Jiang, PM Nussenzweig, GW Goldberg, X Duportet, ... Nature biotechnology 32 (11), 1146, 2014 | 63 | 2014 |
| Comparison of integrases identifies Bxb1-GA mutant as the most efficient site-specific integrase system in mammalian cells B Jusiak, K Jagtap, L Gaidukov, X Duportet, K Bandara, J Chu, L Zhang, ... ACS Synthetic Biology 8 (1), 16-24, 2019 | 38 | 2019 |
| Design and connection of robust genetic circuits A Randall, P Guye, S Gupta, X Duportet, R Weiss Methods in enzymology 497, 159-186, 2011 | 34 | 2011 |
| Modulation of microbiota function by gene therapy of the microbiome to prevent, treat or cure microbiome-associated diseases or disorders X Duportet, A Decrulle, C del Carmen Gil-Cruz, CI Pérez-Shibayama, ... US Patent 11,376,286, 2022 | 8 | 2022 |
| Optimized vector for delivery in microbial populations A Decrulle, JF Rodriguez, X Duportet, D Bikard US Patent 10,808,254, 2020 | 5 | 2020 |
| In situ targeted mutagenesis of gut bacteria AK Brödel, L Charpenay, M Galtier, FJ Fuche, R Terrasse, C Poquet, ... bioRxiv, 2022.09. 30.509847, 2022 | 4 | 2022 |
| Voices of biotech leaders AE Abong, K Bosley, C Casebourn, P Chan, J Chen, M Chen, G Church, ... Nature Biotechnology 39 (6), 654-660, 2021 | 4 | 2021 |
| Modulation of microbiota function by gene therapy of the microbiome to prevent, treat or cure microbiome-associated diseases or disorders X Duportet, A Decrulle, C del Carmen Gil-Cruz, CI Pérez-Shibayama, ... US Patent 11,224,621, 2022 | 3 | 2022 |
| Developing new tools and platforms for mammalian synthetic biology: From the assembly and chromosomal integration of complex DNA circuits to the engineering of artificial … X Duportet Université Paris Diderot (Paris 7), 2014 | 3 | 2014 |
| Optimized vector for delivery in microbial populations A Decrulle, JF Rodriguez, X Duportet, D Bikard US Patent 11,905,516, 2024 | 2 | 2024 |
| Modulation of microbiota function by gene therapy of the microbiome to prevent, treat or cure microbiome-associated diseases or disorders X Duportet, A Decrulle, C del Carmen Gil-Cruz, CI Pérez-Shibayama, ... US Patent 11,534,467, 2022 | 2 | 2022 |
| Optimized vector for delivery in microbial populations A Decrulle, JF Rodriguez, X Duportet, D Bikard US Patent 11,078,490, 2021 | 2 | 2021 |
| Recombinases and target sequences R Weiss, XC Duportet, G Batt, Y Li US Patent 10,731,153, 2020 | 2 | 2020 |
| Optimized vector for delivery in microbial populations A Decrulle, JF Rodriguez, X Duportet, D Bikard US Patent 11,946,056, 2024 | 1 | 2024 |
| Method for killing bacteria with an engineered postbiotic A Decrulle, X Duportet US Patent 11,541,106, 2023 | 1 | 2023 |
